BIOTECH ASSISTANT / FIELD NOTES

Arvinas prioritizes European and UK development of ARV-102 for PSP

Company / institutional announcement · Arvinas

Source published: 2026-11-03

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Arvinas said it will prioritize a Phase 1b study of its LRRK2 degrader ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom. Trial applications and regulatory authorization remain pending. The company continues discussions with US and Japanese regulators, while the US investigational new drug application remains on hold.

Why it may matter

The regional strategy could preserve development momentum, but regulatory clearance and meaningful patient outcomes remain essential tests for neurological protein degradation.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Related updates

2026-11-05Amphista Therapeutics / Business Wire

Amphista previews BRD9 degradation findings and BRAMLIE trial design at ASH

Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.

Protein degradation / PROTAC Ask AI ↗

2026-11-05Nurix Therapeutics

Nurix previews updated bexobrutideg Phase 1 CLL/SLL findings for ASH

Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.

Protein degradation / PROTAC Ask AI ↗

2026-11-04Proceedings of the National Academy of Sciences / PubMed

Bispecific protein drives dual receptor degradation in mouse eye-disease models

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Protein degradation / PROTAC Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗